These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32784819)

  • 1. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer.
    Manzano A; Ocaña A
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32784819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the promising role of antibody drug conjugates in breast and ovarian cancer.
    Babbar R; Vanya ; Bassi A; Arora R; Aggarwal A; Wal P; Dwivedi SK; Alolayan S; Gulati M; Vargas-De-La-Cruz C; Behl T; Ojha S
    Heliyon; 2023 Nov; 9(11):e21425. PubMed ID: 38027672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
    Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
    Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
    Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma.
    Shih CH; Lin YH; Luo HL; Sung WW
    Front Pharmacol; 2024; 15():1326296. PubMed ID: 38572425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
    Zhang L; Fang Y; Kopeček J; Yang J
    Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety.
    Wang Y; Liu L; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates for the treatment of ovarian cancer.
    Calo CA; O'Malley DM
    Expert Opin Biol Ther; 2021 Jul; 21(7):875-887. PubMed ID: 32463296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bystander effect of antibody-drug conjugates: fact or fiction?
    Giugliano F; Corti C; Tarantino P; Michelini F; Curigliano G
    Curr Oncol Rep; 2022 Jul; 24(7):809-817. PubMed ID: 35305211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
    Leal AD; Krishnamurthy A; Head L; Messersmith WA
    Expert Opin Investig Drugs; 2018 Nov; 27(11):901-916. PubMed ID: 30359534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Analysis of Key Factors Related to ADCs Structural Design.
    Tang H; Liu Y; Yu Z; Sun M; Lin L; Liu W; Han Q; Wei M; Jin Y
    Front Pharmacol; 2019; 10():373. PubMed ID: 31068807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives.
    Martín-Sabroso C; Lozza I; Torres-Suárez AI; Fraguas-Sánchez AI
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
    Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
    Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody drug conjugates: Progress, pitfalls, and promises.
    Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
    Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
    Balamkundu S; Liu CF
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.